Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant systemic therapy for patients with node-negative tumors.

I C Henderson1, D F Hayes, L M Parker

  • 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.

Cancer
|May 1, 1990
PubMed
Summary

Adjuvant therapy trials for node-negative patients are raising new questions about treatment benefits and potential long-term toxicities. Further research is needed to determine if these therapies offer a cure for node-negative patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome.

Breast cancer research and treatment·2017

Area of Science:

  • Oncology
  • Clinical Trials
  • Breast Cancer Research

Background:

  • Early adjuvant therapy focused on node-positive patients due to toxicity concerns.
  • Established benefits in node-positive patients led to trials in node-negative patients.
  • Recent trials in node-negative patients yield early results that prompt further inquiry.

Purpose of the Study:

  • To investigate the efficacy and long-term outcomes of adjuvant therapy in node-negative patients.
  • To compare the benefits of adjuvant therapy between node-negative and node-positive patient groups.
  • To assess potential cure rates and the balance of benefits versus delayed toxicities in node-negative patients.

Main Methods:

  • Analysis of data from large-scale, second-generation adjuvant therapy trials.

Related Experiment Videos

  • Comparison of disease-free survival and overall survival rates.
  • Evaluation of potential long-term toxicities and their impact on patient outcomes.

    • Main Results:

    • Early results from node-negative patient trials are available.
    • Questions arise regarding whether mature results will mirror node-positive outcomes or show greater benefits.
    • The possibility of "cure" in node-negative patients is being explored.

    Conclusions:

    • Current data are insufficient to definitively answer questions about adjuvant therapy in node-negative patients.
    • Further investigation is required to understand the long-term benefits and risks.
    • The balance between therapeutic benefits and delayed toxicities remains unclear.